IR News

2022/05/19
Financial Results for Fiscal Year2021
2022/05/12
Consolidated Financial Report for Fiscal Year 2021(April 1, 2021 through March 31, 2022)
2022/05/12
Supplemental Documents for Fiscal Year 2021
2022/04/20
Notice regarding Trade Name Change
2022/04/20
Mid-Term Business Plan (From April 1, 2022 to March 31, 2024)
2022/02/04
Consolidated Financial Report for the 3rd Quarter of the Fiscal Year 2021
2022/02/04
Supplemental Documents for 3rd Quarter of Fiscal Year 2021
2022/02/04
Notice concerning revision (upward revision) of full-year earnings forecast
2022/02/04
Notice concerning recording of extraordinary loss (impairment loss)
2021/11/25
Notice concerning selection of "Prime Market" under new market segments
2021/11/12
Financial Result for 2nd Quarter of Fiscal Year 2021
2021/11/05
Consolidated Financial Report for 2nd Quarter of Fiscal Year 2021(April 1, 2021 through September 30, 2021)
2021/11/05
Supplemental Documents for 2nd Quarter of Fiscal Year 2021
2021/11/05
Notice concerning revision of full-year earnings forecast
2021/11/05
Notice concerning increase in dividend of surplus (interim dividend)
2021/10/14
Notice of passing eligibility examination as active pharmaceutical ingredient (API) producing facility by US Food and Drug Administration (FDA)
2021/08/04
Consolidated Financial Report for 1st Quarter of Fiscal Year 2021(April 1, 2021 through June 30, 2021)
2021/08/04
Supplemental Documents for 1st Quarter of Fiscal Year 2021
2021/06/17
Partial amendment of "NOTICE OF THE 106th ORDINARY GENERAL SHAREHOLDERS' MEETING"
2021/06/16
(Updated) Partial revisions of "Consolidated Financial Results for the Year ended March 31, 2021" and "Supplemental Documents for FY2020"

PageTop